Table 3.

Prevalence of PD-L1 in EGFR/ALK-mutated NSCLC

Category, N (%)	TPS < 1%	TPS 1-49%	TPS ≥ 50%	P-value
ALK status				0.9947
Rearrangement	17 (53.1)	8 (25.0)	7 (21.9)
Wild type	261 (52.2)	128 (25.6)	111 (22.2)
EGFR mutation status				0.0017
Mutant	118 (56.2)	62 (29.5)	30 (14.3)
Wild type	139 (50.2)	62 (22.4)	76 (27.4)
Joint ALK/EGFR Status				0.0009
ALK+ or EGFR+	108 (56.8)	57 (30.0)	25 (13.2)
ALK- and EGFR-	112 (49.8)	50 (22.2)	63 (28.0)

TPS: tumor proportion score; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase